Evaluating the feasibility of lyophilization for oral formulation development of monoclonal antibodies (mAbs)

Objective: To develop a stable lyophilized non-invasive oral formulation of monoclonal antibodies (mAbs) resistant to GI degradation using suitable process optimization parameters for the lyophilization cycle.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

This field is for validation purposes and should be left unchanged.

Evaluating the feasibility of lyophilization for oral formulation development of monoclonal antibodies (mAbs)​

Resources to Consider

Nonclinical Vehicle Formulations:HP-β-CD...

Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug...

Strategies and Solutions for Early Phase Formulation Development and...

Clinical Study of Abuse-Deterrent Formulation to Suppress Release of...

A Competitive Ligand-binding Assay for the Detection of Neutralizing...

WebninarAnalytical Challenges for CMC Development of Cell and Gene...

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...

Companion Diagnostics for Alzheimer’s Disease

Development and validation of an LC-MS/MS method for the...

Validation of a 384 gene hybridization capture-based pharmacogenomics...

Immunoassays for Drug Discovery

Testing of Carryover & After MRD Benchtop Stability for...

Evaluating the feasibility of lyophilization for oral formulation development of monoclonal antibodies (mAbs)